Hikma Pharmaceuticals LLC
Quick facts
Marketed products
- Biosimilar Infliximab · Immunology / Rheumatology / Gastroenterology
Biosimilar infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Phase 2 pipeline
- Carcemia · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: